140 related articles for article (PubMed ID: 32269142)
1. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy.
Schroeder BA; Black RG; Spadinger S; Zhang S; Kohli K; Cao J; Mantilla JG; Conrad EU; Riddell SR; Jones RL; Yee C; Pollack SM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269142
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
3. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
4. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
5. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.
Zhang S; Kohli K; Black RG; Yao L; Spadinger SM; He Q; Pillarisetty VG; Cranmer LD; Van Tine BA; Yee C; Pierce RH; Riddell SR; Jones RL; Pollack SM
Cancer Immunol Res; 2019 Aug; 7(8):1237-1243. PubMed ID: 31171504
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
9. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
Evans R; Kamdar SJ; Duffy T; Edison L
J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A; Ishihara M; Nakamura T; Kitano S; Iwata S; Takada K; Emori M; Kato K; Endo M; Matsumoto Y; Kakunaga S; Sato E; Miyahara Y; Morino K; Tanaka S; Takahashi S; Matsuo F; Matsumine A; Kageyama S; Ueda T
Clin Cancer Res; 2023 Dec; 29(24):5069-5078. PubMed ID: 37792433
[TBL] [Abstract][Full Text] [Related]
11. The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.
Segal JG; Lee NC; Tsung YL; Norton JA; Tsung K
Cancer Res; 2002 Aug; 62(16):4696-703. PubMed ID: 12183428
[TBL] [Abstract][Full Text] [Related]
12. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.
Mihalyo MA; Doody AD; McAleer JP; Nowak EC; Long M; Yang Y; Adler AJ
J Immunol; 2004 May; 172(9):5338-45. PubMed ID: 15100273
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
14. The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
Pollack SM
Expert Rev Vaccines; 2018 Feb; 17(2):107-114. PubMed ID: 29280411
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
16. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
[TBL] [Abstract][Full Text] [Related]
17. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
19. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.
Becker C; Pohla H; Frankenberger B; Schüler T; Assenmacher M; Schendel DJ; Blankenstein T
Nat Med; 2001 Oct; 7(10):1159-62. PubMed ID: 11590442
[TBL] [Abstract][Full Text] [Related]
20. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]